| W |
|
WALL CLOT GROWTH IN PLASMA: EFFECT OF HIGH DOSES RECOMBINANT FVIIA
|
| Bordet J., Plantier J., Ovanesov M., Volpert V., Ataullakhanov F., Negrier C. |
| |
|
WARFARIN ANTICOAGULATION INTENSITY IN SPECIALIST-BASED AND IN COMPUTER -ASSISTED DOSING PRACTICE
|
| Onundarson P.T., Einarsdottir K.A., Gudmundsdottir B.R. |
| |
|
WARFARIN PHARMACOGENOMICS: A MULTIPLEX METHOD FOR CYP2C9 AND VKORC1 GENOTYPING
|
| Sanders A., Morgan L., Dolan G., Hill M. |
| |
|
WARFARIN USE AND THE DECREASED RISK OF PROSTATE CANCER
|
| Opatrny L., Delaney J.A., Tagalakis V., Kahn S.R., Suissa S. |
| |
|
WASHOUT PERIOD AND FVIII:C IN PATIENTS WITH SEVERE HEMOPHILIA A
|
| van Dijk K., Fischer K., van der Bom J.G., de Groot P.G., van den Berg H. |
| |
|
WHAT DO ELEVATED D-DIMER LEVELS MEAN IN PATIENTS WITHOUT VENOUS THROMBOSIS (VTE)?
|
| Bacchu S., Paneesha S., French K., Cheyne E., Borg A., Rose P. |
| |
|
WHAT DO WE EXPECT FROM THE INTERNATIONAL REGISTRY?
|
| Peyvandi F. |
| |
|
WHAT DOES HIGH PREVALANCE OF FACTOR V LEIDEN MUTATION IN POLISH SEVERE HAEMOPHILIACS MEAN?
|
| Windyga J., Buczma A., Stefanska E., Bykowska K., Baran B. |
| |
|
WHAT IS THE CLINICAL IMPACT OF PLASMINOGEN-ACTIVATOR INHIBITOR (PAI-1) DEFICIENCY?
|
| Santamaría A., Borrell M., Mateo J., Vallve C., Fontcuberta J. |
| |
|
WHICH PATIENTS WITH VENOUS THROMBOSIS DO NOT REQUIRE SCREENING FOR MALIGNANCY? A PREDICTIVE MODEL TO IDENTIFY PATIENTS WITH VTE AT MINIMAL RISK OF MALIGNANCY
|
| Paneesha S., Zhang W., Parsons N., Kesteven P., Marr H., Borg A., Rose P. |
| |
|
WHOLE BLOOD AND PLASMA THROMBIN GENERATION ASSAYS IN PATIENTS WITH A HISTORY OF VENOUS THROMBOEMBOLISM
|
| Tappenden K.A., Gallimore M.J., Evans G., Winter M., Mackie I.J., Jones D.W. |
| |
|
WHOLE BLOOD CLOTTING TIME (WBCT) COMPARED TO IN VIVO DOSE RESPONSE OF RFVIIA IN FVIII-KO MICE
|
| Elm T., Ezban M., Tranholm M. |
| |
|
WHOLE BLOOD PROCOAGULANT ACTIVITY: A POSSIBILE CELLULAR MARKER OF CARDIOVASCULAR RISK?
|
| Napoleone E., Zurlo F., Gozdzikiewicz J., Costanzo S., Vohnout B., Iacoviello L., Donati M., Lorenzet R. |
| |
|
WHOLE-BLOOD CLOTTING FOR EVALUATING THROMBIN GENERATION IN CHRONIC LIVER FAILURE
|
| Carmassi F., de Bortoli N., Pietrini P., Marchi S., De Negri F., Pentimone F. |
| |
